Caspofungin acetate: An antifungal agent

American Journal of Health-System Pharmacy

Volumn 58, Issue 13, 2001, Pages 1206-1214

  Hoang, A ^a   Kay, L ^a  

^a University HealthSystem Consortium   (United States)

Author keywords

Antifungals; Caspofungin acetate; Drug interactions; Mechanism of action; Mycoses; Pharmacokinetics; Toxicity

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN;

ASPERGILLOSIS; CANDIDA ALBICANS; CELL DESTRUCTION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG INHIBITION; DRUG STRUCTURE; DRUG TOLERABILITY; ESOPHAGITIS; FUNGICIDAL ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STRUCTURE ANALYSIS;

EID: 0035397313     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/58.13.1206     Document Type: Review

References (49)

1. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
2. Resistance of Candida species to fluconazole
3. Caspofungin: L-743,872, MK 0991, MK 991
4. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
5. Echinocandins and pneumocandins - A new antifungal class with a novel mode of action
6. Treatment of murine disseminated candidiasis with L-743,872
7. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
8. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species
9. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
10. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans
11. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
12. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species
13. International surveillance of blood stream infections due to Candida species in the European SENTRY program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents
14. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans
15. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents
16. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds
17. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi
18. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates
19. In vitro susceptibility of clinical trial isolates of Aspergillus spp. to the echinocandin antifungal Caspofungin (Cancidas™, MK-0991)
20. Treatment of histoplasmosis with MK-991 (L-743,872)
21. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872
22. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model
23. In vitro synergy studies with caspofungin and amphotericin B against Aspergillus and Fusarium
24. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro
25. 1, fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans
26. Single-and multiple-dose pharmacokinetics of the antifungal agent MK-0991 in man
27. Single dose caspofungin pharmacokinetics in healthy elderly subjects
28. A phase I study of caspofungin evaluating the potential for drug interactions with itraconazole, the effect of gender and the use of a loading dose regimen
29. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872)
30. The influence of human sera on the in vitro activity of MK-0991 against Aspergillus fumigatus
31. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, amphotericin B lipid formulations, or azoles
32. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
33. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii
34. The glucan synthesis inhibitor caspofungin acetate (Cancidas™, MK-0991, L-743,872) kills Aspergillus fumigatus hyphal tips in vitro and is efficacious against disseminated aspergillosis in cyclophosphamide-induced chronically leukopenic mice
35. Collaboration of human monocytes and monocyte-derived macrophages with MK-0991 for antifungal activity against Aspergillus fumigatus
36. A randomized, double-blind, multicenter trial of MK-0991, an echinocandin antifungal agent, vs. amphotericin B for the treatment of oropharyngeal and esophageal candidiasis in adults
37. Versicor V-echinocandin vs fluconazole phase III planned for 2001
38. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi
39. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis
40. In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species
41. Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors
42. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole
43. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum
44. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B
45. Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model
46. Efficacy of nikkomycin Z against experimental pulmonary blastomycosis
47. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole
48. Antifungal agents. Part II. The azoles
49. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations